Shanghai, China, August 18, 2026
WuXi Biologics has been recognized by BioPharma APAC among its Top 26 companies leading sustainable biopharma practices in 2026, highlighting the company’s efforts to integrate sustainability across biologics research, development, manufacturing and operations. The recognition places particular emphasis on WuXi Biologics’ Green CRDMO approach, which is designed to embed environmental efficiency into the end-to-end biopharmaceutical value chain rather than treating sustainability as a separate corporate initiative. The company is using technology, process optimization, digital tools and resource-efficient manufacturing approaches to help biopharmaceutical clients address growing requirements around carbon reduction, resource efficiency, Scope 3 emissions and product-level environmental transparency. WuXi Biologics’ sustainability strategy connects green practices with operational productivity, supply-chain resilience and manufacturing efficiency, positioning Green CRDMO as an integrated service capability for partners developing and manufacturing biologic medicines.
Green Research and Development Platforms Improve Efficiency
WuXi Biologics is incorporating sustainability into its research and development platforms to reduce development timelines and improve resource efficiency. Its integrated CRDMO capabilities and technologies such as WuXiBody™ are designed to accelerate antibody and complex-molecule development while improving developability and stability. The company states that WuXiBody™ can simplify bispecific antibody development and shorten R&D timelines by 6–18 months, potentially reducing the resources and energy required during development. In process development, platforms including WuXia™, WuXiUP™ and WuXiUI™ are being used to improve productivity and create more efficient manufacturing pathways. WuXi Biologics reports that its WuXia™ TrueSite cell line development platform can achieve monoclonal antibody titers of 8–12 g/L, while WuXiUI™ can increase productivity by 3 to 8 times and reduce lifecycle environmental impacts by up to 60% compared with traditional fed-batch processes. These technologies form a key part of the company’s strategy to connect bioprocess innovation with sustainability and operational efficiency.
Green Manufacturing Targets Lower Resource and Carbon Use
Manufacturing efficiency is another major component of WuXi Biologics’ Green CRDMO strategy. The company is using single-use technology (SUT) and process innovations to reduce water consumption, resource requirements and climate-related impacts compared with conventional stainless-steel manufacturing processes. WuXi Biologics reports that SUT can reduce water consumption by up to 70%, resource use by approximately 33%, and climate-change impacts by approximately 40% compared with traditional stainless-steel processes. When combined with WuXiUI™ technology, the company states that manufacturing can achieve reductions of up to 80% in product carbon footprint per gram of protein. WuXi Biologics is also applying lifecycle assessment (LCA) capabilities to support cradle-to-gate product carbon-footprint measurement, giving clients greater visibility into environmental impacts and supporting efforts to manage Scope 3 emissions and value-chain decarbonization. Waste-management initiatives, including zero-waste-to-landfill efforts, waste-to-energy utilization and exploration of SUT recycling approaches, further support the company’s manufacturing sustainability objectives.
Advertisement
Sustainability Integrated Across Global CRDMO Operations
Beyond individual manufacturing technologies, WuXi Biologics is embedding sustainability across its global operations through energy-efficiency programs, renewable energy adoption, lean management and digital tools. The company’s Green CRDMO White Paper documents 242 energy-saving cases covering 12 major energy systems, five energy-saving scenarios and 25 categories of energy-saving technologies, providing a framework for applying operational sustainability practices across its sites and value chain. WuXi Biologics has also obtained Science Based Targets initiative (SBTi) validation for its near-term, long-term and net-zero targets and has committed to achieving net-zero emissions across its value chain by 2050. The company’s Green CRDMO approach has additionally received external sustainability recognition, including selection as a United Nations Global Compact sustainability case. With sustainability increasingly becoming a strategic consideration for biopharmaceutical manufacturing and supply chains, WuXi Biologics is positioning Green CRDMO as a way to combine environmental performance with productivity, resilience and scalable biologics manufacturing.
Source: WuXi Biologics press relese
